Idiopathic Pulmonary Fibrosis (IPF) – Market Access and Reimbursement Insights Report – 2025

Idiopathic Pulmonary Fibrosis (IPF) Market Access and Reimbursement Insights

Thelansis’s “Idiopathic Pulmonary Fibrosis (IPF) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Idiopathic Pulmonary Fibrosis (IPF) Overview

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease of unknown cause, defined by a usual interstitial pneumonia (UIP) pattern on high‑resolution CT or histopathology. It typically presents in adults over 60 years with exertional dyspnea and a persistent dry cough, and clinicians often detect fine “Velcro‑like” inspiratory crackles at the lung bases on examination. IPF belongs to the subgroup of idiopathic interstitial pneumonias within the broader category of diffuse parenchymal lung diseases. The disease course is marked by gradual scarring of lung tissue, leading to worsening respiratory function and reduced survival.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Idiopathic Pulmonary Fibrosis (IPF) – Market Access and Reimbursement Insights Report – 2025